Read all news items about the AGE Reader and Diagnoptics.
Groningen, the Netherlands – November 5th 2018,
In the Netherlands, as in most other countries, the impact of diabetes in terms of health and cost is very large and still increasing.
In addition, forty percent of diabetes patients have not yet been diagnosed. It is precisely through early detection of people who are at an increased risk of developing diabetes that there is much health gain to be achieved, both for public health and for the individual.
This can prevent (chronic) complications, such as cardiovascular disease. However, currently an accessible and easy way to pre-medically screen people does not exist. That is why Diagnoptics in cooperation with Dutch pharmacy ‘de Vriendschap’ is developing a diabetes risk test prototype based on the non-invasive AGE measurement.
By performing this test at the pharmacy clients can easily check whether they are at an increased risk of developing diabetes and receive further advice. This project is made possible through a contribution of the European Union from the Europees Fonds voor Regionale Ontwikkeling (EFRO).
Would you like to learn more about our products? Request any information you wish to receive here.
If you want to receive the newsletter with information about DiagnOptics' products, please send us your email address.
More information about Diagnoptics.
Information on Diagnoptics' products and Advanced Glycation Endproducts.
Information about Advanced Glycation Endproducts, the AGE measurement and clinical validation.